The acne clinical trial to understand is a Phase 3 test of denifanstat, an oral once-daily drug for moderate-to-severe acne. It met its main goals at 12 weeks, then showed continued lesion improvement through 52 weeks of treatment. That result matters for people who need options beyond antibiotics. Use it as one data point, not a prescription, and weigh the limits and next steps below.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from Financialcontent — Use this primary source to verify the official guidance.
- Read the official guidance from Org — Use this primary source to verify the official guidance.
Table of Contents
- What did the 12-week trial show?
- How much did lesions improve by one year?
- What did safety look like?
- Why should long-term gains be read with care?
- What should readers do next?
What did the 12-week trial show?
Ascletis tested 50 mg oral denifanstat once daily against placebo for 12 weeks. The study enrolled 480 Chinese patients with moderate-to-severe acne.
According to Dermatology Times, the trial met all primary and secondary endpoints the Dermatology Times report on the 12-week Phase 3 result. Short trials test whether a drug beats placebo under tight control. A win here supports longer testing, not routine use yet.
How much did lesions improve by one year?
Patients who continued into the 40-week open-label extension ASC40-304 reached 52 weeks total treatment. According to Dermatology Times, that group reached 56.7% Investigator's Global Assessment treatment success, with 71.8% mean total-lesion reduction and 76.9% inflammatory-lesion reduction the Dermatology Times report on 52-week results.
Investigator's Global Assessment success means a doctor rated skin clear or almost clear. Total counts track all visible lesions, while inflammatory counts track red and painful bumps.
What did safety look like?
According to Dermatology Times, treatment through 52 weeks caused no adverse-event-related permanent discontinuations and no drug-related serious adverse events the Dermatology Times safety summary through 52 weeks. Common treatment-related events were dry skin at 7.1% and dry eye at 5.9%.
Dryness can affect daily comfort, contact-lens wear, and skin barrier care. Tell your clinician about eye or skin dryness before changing moisturizers, drops, or lenses.
Why should long-term gains be read with care?
ASC40-304 was open-label without placebo and enrolled only 240 completers from the parent trial. Efficacy was measured against parent-trial baseline.
Dermatology Times notes those long-term gains may reflect selection, expectation, or time effects. People who stay in extensions often do better than those who leave. Without a placebo group, time alone and expectation can look like drug benefit.
What should readers do next?
Sagimet received FDA IND clearance and a Study May Proceed letter for denifanstat in moderate-to-severe acne, according to Sagimet the Sagimet FDA clearance announcement. Sagimet plans a U.S. AURORA trial for about 800 patients aged 12 and older. The planned AURORA design uses a 12-week randomized double-blind period, Dermatology Times reports.
It will assess co-primary IGA-success and lesion-count endpoints, followed by a 40-week open-label extension for long-term safety. NICE guideline NG198 directs clinicians to warn about relapse and offer maintenance therapy such as adapalene plus benzoyl peroxide. It directs review of maintenance after 12 weeks to decide continuation. Medscape reporting on a 19,907-patient JAMA Dermatology cohort found 22.5% had acne relapse requiring systemic treatment. In that cohort, 8.2% needed isotretinoin retrial, with higher cumulative dose protective and female sex raising relapse risk.
- Ask your dermatologist whether maintenance treatment fits after clearance
- Ask what relapse signs should prompt a return visit
- Ask where to find enrollment information if AURORA participation interests you
- Bring your treatment history and ask what maintenance and follow-up plan fits you